PfSPZ Vaccine is first to show durable, sterile protection in people with no prior infection.
Bethesda, MD-(ENEWSPF)- An experimental malaria vaccine protected a small number of healthy, malaria-naïve adults in the United States from infection for more than one year after immunization, according to results from a Phase 1 trial described in the May 9th issue of Nature Medicine. The vaccine, known as the PfSPZ Vaccine, was developed and produced by Sanaria Inc., of Rockville, Maryland,…
